ImmunoCAP® 250
Automation and quality in allergy testing

Phadia
**A family to grow with**

When your allergy testing grows you can simply add new ImmunoCAP® instrumentation without having to abandon your previous system. The unique ImmunoCAP® Information Data Manager software allows you to integrate several ImmunoCAP instruments into one network without having to learn new software.

**ImmunoCAP® 250**

Allergic diseases are a rapidly growing health problem. A precise, reliable in vitro test for IgE antibodies to specific substances is a valuable tool to support the clinician in making diagnosis of or excluding allergy, prescribing and following up treatment, and predicting disease development.

ImmunoCAP® 250 builds on the reliability and well-proven technology found in ImmunoCAP® 100® and ImmunoCAP® 1000 to provide the ultimate solution, including automation, quality and throughput for the medium sized allergy testing laboratory. With user-friendly operating software and browser-like test and reference documentation onboard ImmunoCAP® 250 really makes the difference.

---

**ImmunoCAP® Information Data Manager**

- Requests (Patient and/or Sample ID)
- Result management
- Quantitative results
- QC management
- Instrument monitoring
- Patient result database
- Stock management
- Process monitoring
- Graphical result reports
**Higher capacity and automation for increased productivity**

- Ideal for medium-sized laboratories running 80-400 tests/day
- Fully automated, continuous random access and mainframe connection
- Throughput: 60 tests/hour
- Positive identification and full traceability of all samples and reagents
- All reagents and up to 3,000 tests on-board
- Up to 6 different methods
- Automatic sample dilution
- Stand alone PC hosting the IDM system software
- Built-in touch screen

**Common ImmunoCAP® features**

- World-leading ImmunoCAP technology providing accurate and reproducible test results
- True quantitative measurements
- Large panel of standardized high-quality allergens

**Automation for walk-away productivity**

The ImmunoCAP® systems are all highly automated, requiring minimal hands-on time. Choosing the system with the capacity matching your needs for throughput ensures optimal productivity.

A typical work-day schedule for ImmunoCAP® 250 is shown below.

---

**Technical information**

- **Foot print:** 127 x 75 cm
- **Weight:** 220 kg
- **Power supply:** 100, 120, 220, 230, 240 V / 50 - 60 Hz / 1.2 kVA
- **Environmental temperature:** 18 - 32 °C
- **Operating system:** Windows® 2000 / Windows® XP
- **Mainframe connection protocol:** ASTM, MasterCAP™ and Phamas
- **Clustering:** Optional
Thirty years of market leadership

Phadia developed in vitro allergy testing in the early 1970’s. We pioneered allergy test development and developed the allergen code standard. Today’s ImmunoCAP® systems are the result of thirty years of technology, chemistry and instrument development. ImmunoCAP systems are the most frequently used in routine testing and in clinical studies – the reference systems in allergy testing.

The development history includes several important milestones:

1st generation

1974 – Phadebas RAST

The first laboratory test for specific IgE-antibodies. The paper disc technology combining quality with a large panel of allergens became the “gold standard” of allergy testing.

2nd generation

1989 – Pharmacia CAP System®

The ImmunoCAP technology brought new standards of quality and capacity to the market, also introducing semi-automation to increase laboratory efficiency.

3rd generation

1996 – UniCAP® 100

Introducing full automation and quick assay procedure. Further improvements in precision and reproducibility through improved chemistry, standardized handling and environmental control laid the foundation for truly quantitative measurements. Already 4000 instruments on the market.

4th generation

2001/2004 – ImmunoCAP® 1000 and 250

The unsurpassed quality of ImmunoCAP® 100 combined with even higher automation, speed, capacity and continuous random access ability.

All systems are CE-marked according to 98/79/EC; in vitro diagnostic medical device directive for all EU countries and including Norway and Switzerland.